ELTROMBOPAG OLAMINE

Eltrombopag Olamine is a thrombopoietin receptor agonist used to stimulate platelet production in patients with thrombocytopenia. It is commonly prescribed for chronic immune thrombocytopenia (ITP), severe aplastic anemia, and thrombocytopenia associated with hepatitis C.

Indications

-Chronic immune thrombocytopenia (ITP) in adults and children who have had an insufficient response to other treatments -Severe aplastic anemia -Thrombocytopenia in patients with chronic hepatitis C to allow for interferon-based therapy

Dosage

-Adult Dose: Typically, 50 mg once daily. However, patients of East Asian descent or those with hepatic impairment may start at 25 mg. -Pediatric Dose: Varies based on body weight and indication. -The dose may be adjusted based on platelet response and liver function.

Contra-Indications

-Hypersensitivity to Eltrombopag or any of its components -Severe hepatic impairment -Patients with a history of thromboembolic events

Special Precautions

-Regular monitoring of liver function tests -Increased risk of thrombotic events at higher platelet counts -Should not be used as an emergency treatment for bleeding -Avoid taking with dairy products, calcium-rich foods, or antacids, as they reduce drug absorption

Side Effects

-Nausea, vomiting -Headache -Liver enzyme elevation -Fatigue -Thromboembolic events in rare cases

Drug Interactions

-Antacids and calcium-containing foods reduce absorption -Strong CYP1A2 inhibitors/inducers may alter drug metabolism -Increased risk of hepatotoxicity with other hepatotoxic drugs